Adding Single-Dose Fosaprepitant Improves CINV Control

Share this content:
Addition of single-dose fosaprepitant was well tolerated and demonstrated superior control of chemotherapy-induced nausea and vomiting.
Addition of single-dose fosaprepitant was well tolerated and demonstrated superior control of chemotherapy-induced nausea and vomiting.

The addition of single-dose fosaprepitant, the intravenous formulation of aprepitant, to a 5-HT3 receptor antagonist and dexamethasone was well tolerated and demonstrated superior control of chemotherapy-induced nausea and vomiting (CINV) associated with non-anthracycline and cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC), a new study published online ahead of print in the journal Annals of Oncology has shown.1

For the international, double-blind, phase 3 trial, researchers randomly assigned adult patients scheduled to receive non-AC MEC on day 1 to a regimen consisting of fosaprepitant 150 mg intravenously or placebo in addition to ondansetron plus dexamethasone on day 1. Those in the control group received ondansetron on days 2 and 3 as well.

Results showed that the single-dose fosaprepitant regimen significantly improved complete response in the delayed (78.9% vs 68.5%; P<0.001) and overall (77.1% vs 66.9%; P<0.001) phases; however, complete response was not improved in the acute phase (93.2% vs 91.0%; P=0.184) compared with control.

Researchers found that fosaprepitant also improved the proportion of patients with no vomiting (82.7% vs 72.9%; P<0.001) and no significant nausea (83.2% vs 77.9%; P=0.030) vs placebo.

RELATED: FDA Approves Varubi for Chemo-Induced Nausea and Vomiting

In regard to safety, the fosaprepitant regimen was generally well tolerated.

This is the first study to assess a neurokinin-1 receptor antagonist as an intravenous formulation in a population receiving non-AC MEC.

Reference

  1. Weinstein C, Jordan K, Green S, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial [published online ahead of print in the journal Annals of Oncology]. Ann Oncol. doi: 10.1093/annonc/mdv482.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters